Tibet AIM Pharm. Inc. (SHE:002826)
China · Delayed Price · Currency is CNY 19.50
-0.02 (-0.10%)
Apr 30, 2026, 3:04 PM CST
Tibet AIM Pharm. Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 670.32 | 636.27 | 649.72 | 666.8 | 856.53 | 724.36 |
Other Revenue | - | - | 2.16 | 0.23 | 0.21 | 1.1 |
| 670.32 | 636.27 | 651.88 | 667.04 | 856.73 | 725.46 | |
Revenue Growth (YoY) | 4.74% | -2.40% | -2.27% | -22.14% | 18.09% | 20.38% |
Cost of Revenue | 115.9 | 113.81 | 205.54 | 325.59 | 480.7 | 464.96 |
Gross Profit | 554.41 | 522.46 | 446.34 | 341.45 | 376.03 | 260.5 |
Selling, General & Admin | 452.39 | 433.58 | 390.65 | 298.35 | 317.92 | 218.48 |
Research & Development | 14.07 | 14.67 | 15.48 | 13.71 | 13.35 | 11.39 |
Other Operating Expenses | -14.31 | -24.39 | 12.27 | 11.5 | -8.2 | -9.81 |
Operating Expenses | 452.15 | 423.86 | 419.08 | 316.54 | 329.71 | 218.93 |
Operating Income | 102.26 | 98.6 | 27.26 | 24.91 | 46.32 | 41.58 |
Interest Expense | - | - | -0.45 | -1.18 | -0.81 | -0.84 |
Interest & Investment Income | 3.55 | 3.5 | 5.2 | 5.06 | 3.93 | 2.92 |
Currency Exchange Gain (Loss) | - | - | 0 | 0 | 0 | -0 |
Other Non Operating Income (Expenses) | 14.57 | 14.54 | -0.3 | 1.06 | 3.23 | 2.8 |
EBT Excluding Unusual Items | 120.38 | 116.63 | 31.71 | 29.85 | 52.68 | 46.46 |
Impairment of Goodwill | - | - | - | -19.8 | - | - |
Gain (Loss) on Sale of Assets | -0.09 | -0.23 | -0.04 | 0.03 | - | 0.03 |
Asset Writedown | -2.72 | -2.73 | -0.2 | -0.13 | -0.08 | -0.08 |
Other Unusual Items | - | - | 28.91 | 13.65 | 4.1 | 3.6 |
Pretax Income | 117.57 | 113.67 | 60.38 | 23.6 | 56.7 | 50.01 |
Income Tax Expense | 23.73 | 20.55 | 12.92 | 7.87 | 10.59 | 6.54 |
Earnings From Continuing Operations | 93.84 | 93.12 | 47.46 | 15.73 | 46.12 | 43.47 |
Minority Interest in Earnings | -0.41 | -0.54 | -1.53 | -0.34 | -1.98 | -1 |
Net Income | 93.44 | 92.58 | 45.93 | 15.39 | 44.14 | 42.48 |
Net Income to Common | 93.44 | 92.58 | 45.93 | 15.39 | 44.14 | 42.48 |
Net Income Growth | 153.74% | 101.57% | 198.50% | -65.14% | 3.91% | 3.37% |
Shares Outstanding (Basic) | 183 | 185 | 184 | 192 | 192 | 193 |
Shares Outstanding (Diluted) | 183 | 185 | 184 | 192 | 192 | 193 |
Shares Change (YoY) | -0.74% | 0.79% | -4.48% | 0.23% | -0.61% | 3.37% |
EPS (Basic) | 0.51 | 0.50 | 0.25 | 0.08 | 0.23 | 0.22 |
EPS (Diluted) | 0.51 | 0.50 | 0.25 | 0.08 | 0.23 | 0.22 |
EPS Growth | 155.64% | 100.00% | 212.50% | -65.22% | 4.54% | - |
Free Cash Flow | 163.39 | 115.22 | 99.33 | 163.7 | 65.26 | 84.33 |
Free Cash Flow Per Share | 0.89 | 0.62 | 0.54 | 0.85 | 0.34 | 0.44 |
Dividend Per Share | - | - | 0.100 | 0.030 | 0.100 | 0.100 |
Dividend Growth | - | - | 233.33% | -70.00% | - | 25.00% |
Gross Margin | 82.71% | 82.11% | 68.47% | 51.19% | 43.89% | 35.91% |
Operating Margin | 15.26% | 15.50% | 4.18% | 3.73% | 5.41% | 5.73% |
Profit Margin | 13.94% | 14.55% | 7.05% | 2.31% | 5.15% | 5.85% |
Free Cash Flow Margin | 24.38% | 18.11% | 15.24% | 24.54% | 7.62% | 11.62% |
EBITDA | 120.79 | 117.73 | 48.82 | 49.05 | 69.02 | 65.24 |
EBITDA Margin | 18.02% | 18.50% | 7.49% | 7.35% | 8.06% | 8.99% |
D&A For EBITDA | 18.53 | 19.14 | 21.55 | 24.14 | 22.7 | 23.66 |
EBIT | 102.26 | 98.6 | 27.26 | 24.91 | 46.32 | 41.58 |
EBIT Margin | 15.26% | 15.50% | 4.18% | 3.73% | 5.41% | 5.73% |
Effective Tax Rate | 20.18% | 18.07% | 21.39% | 33.37% | 18.67% | 13.08% |
Revenue as Reported | - | - | 651.88 | 667.04 | 856.73 | 725.46 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.